peramivir · Biocryst · NDA 206426
Rapivab
Earliest generic entry, as listed
7 May 2027
Blocked by patent: US 8778997. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 2 unexpired
5 Orange Book listing rows for 2 patents. FDA lists a patent once for each use code, and lists its pediatric extension as a separate row.
| Patent | Claims | Expires |
|---|---|---|
| US 8778997 | use U-1627, U-2622, U-3069 | 7 May 2027 |
| US 8778997 listing row | use U-1627 · sets the listed date | 7 May 2027 |
| US 8778997 listing row | use U-2622 · sets the listed date | 7 May 2027 |
| US 8778997 listing row | use U-3069 · sets the listed date | 7 May 2027 |
| US 10391075 | use U-2622, U-3069 | 12 Feb 2027 |
| US 10391075 listing row | use U-2622 | 12 Feb 2027 |
| US 10391075 listing row | use U-3069 | 12 Feb 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- Enters 12-month window basis: patent, carve-out possible · 206426-001Listed date 7 May 2027Detected 24 Oct 2026
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 206426 · 001 · RLD | solution, intravenous | 200MG/20ML (10MG/ML) | 7 May 2027 |